系统性红斑狼疮胃肠道表现治疗的系统综述
该系统综述检索1990年1月至2022年6月MEDLINE、EMBASE、PubMed和Cochrane数据库,纳入29项研究共767例患者,评估系统性红斑狼疮胃肠道表现的治疗证据。多数研究显示,严重或危及生命的表现可从静脉甲泼尼龙冲击治疗中获益,较轻表现可从口服泼尼松获益,但证据质量低且所有研究均存在高偏倚风险。作者呼吁标准化疾病定义和术语,并将胃肠道表现纳入疾病评分系统。
要点
- 多数研究显示静脉甲泼尼龙冲击治疗对严重或危及生命的胃肠道表现有益,口服泼尼松用于较轻表现。
- 纳入29项研究共767例患者,包括6项队列研究、11项病例对照研究和11项病例系列。
- 所有研究证据质量低且存在高偏倚风险,作者认为亟需高质量临床试验。
核心结论
- 本综述强调需要标准化的疾病定义和术语,并考虑将胃肠道表现纳入疾病评分系统。
- 作者认为亟需针对系统性红斑狼疮胃肠道表现治疗的高质量临床试验,且很可能需要多中心开展。
- 作者希望本综述能提高对系统性红斑狼疮胃肠道表现的认识,并作为循证治疗的实用指南。
研究设计与样本
- 系统检索1990年1月至2022年6月的MEDLINE、EMBASE、PubMed和Cochrane数据库,检索词涉及胃肠道系统、系统性红斑狼疮和治疗。
- 当某一表现有足够治疗证据时,排除病例数少于10例的病例系列和病例报告;对于证据不足的罕见表现,纳入较小的病例系列和病例报告。
- 共纳入29项研究767例患者,包括6项队列研究、11项病例对照研究和11项病例系列。
主要发现
- 具体胃肠道表现包括肠炎(5项研究)、肠系膜血管炎(3项研究)、急性胰腺炎(5项研究)、慢性胰腺炎(1项研究)、肠假性梗阻(2项研究)、肝炎(4项研究)、蛋白丢失性肠病(6项研究)、急性非结石性胆囊炎(2项研究)和Budd-Chiari综合征(1项研究)。
- 腹水(13例病例报告)、腹膜炎(3例病例报告)和其他胃肠道表现(11例病例报告)的治疗证据作为补充文件纳入。
- 多数研究显示静脉甲泼尼龙冲击治疗对严重或危及生命的表现有益,口服泼尼松用于较轻表现。
- 所有研究证据质量低且存在高偏倚风险。
临床怎么用
- 作者希望本综述能作为系统性红斑狼疮胃肠道表现循证治疗的实用指南。
- 作者认为需要标准化的疾病定义和术语,并考虑将胃肠道表现纳入疾病评分系统。
- 作者认为亟需高质量临床试验,且很可能需要多中心开展。
局限性
- 所有研究证据质量低且存在高偏倚风险。
- 作者认为亟需高质量临床试验,且很可能需要多中心开展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To comprehensively assess and present the evidence for treatments used in the management of the gastrointestinal manifestations of SLE. METHODS: A systematic search of the literature from January 1990 to June 2022 was performed using the following databases: MEDLINE, EMBASE, PubMed and Cochrane. Key words relating to the gastrointestinal system, SLE, and treatment were used. Where there was sufficient evidence for the treatment of a manifestation, we excluded case series with <10 cases and case reports. However, for rarer manifestations with insufficient higher-level evidence, smaller case series and case reports were included. RESULTS: A total of 29 studies including 767 patients were included in the review; six cohort studies, 11 case-control studies, and 11 case series. Specific gastrointestinal manifestations included enteritis (5 studies), mesenteric vasculitis (3 studies), acute pancreatitis (5 studies), chronic pancreatitis (1 study), intestinal pseudo-obstruction (IPO) (2 studies), hepatitis (4 studies), protein-losing enteropathy (PLE) (6 studies), acute acalculous cholecystitis (2 studies), and Budd-Chiari Syndrome (1 study). Evidence for the treatment of Ascites (13 case reports), peritonitis (3 case reports), and miscellaneous GI manifestations (11 case reports) are included as a supplemental file. Most studies demonstrated a benefit from pulsed intravenous methylprednisolone (IVMP) in severe or life-threatening manifestations, and oral prednisolone for less severe manifestations. However, the quality of evidence was low, with a high risk of bias in all studies. CONCLUSION: This review highlights the need for standardised disease definitions and terminology, as well as consideration of including gastrointestinal manifestations in disease scoring systems. There is a significant need for high-quality clinical trials in the treatment of the gastrointestinal manifestations of SLE, which will likely need to be multi-centre. We hope that this review will promote awareness of the gastrointestinal manifestations of SLE, and serve as a practical guide for evidence-based treatment.
引用
- Williamson L, Hao Y, Basnayake C, et al. Systematic review of treatments for the gastrointestinal manifestations of systemic lupus erythematosus. Semin Arthritis Rheum. 2024. PMID: 39461088. doi:10.1016/j.semarthrit.2024.152567
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。